Artiva Biotherapeutics, Inc. (ARTV)
(Delayed Data from NSDQ)
$15.83 USD
+0.43 (2.79%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $15.81 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARTV 15.83 +0.43(2.79%)
Will ARTV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ARTV based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ARTV
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Buy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial Optimism
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics GAAP EPS of -$22.00
Wedbush bullish on Artiva Biotherapeutics, initiates with an Outperform